<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-QR0505OX</identifier><date>2004</date><creator>Zakotnik, Branko</creator><relation>documents/doc/Q/URN_NBN_SI_doc-QR0505OX_001.pdf</relation><relation>documents/doc/Q/URN_NBN_SI_doc-QR0505OX_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 57-61</format><identifier identifier_type="COBISSID_HOST">18866137</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-QR0505OX</identifier><language>slv</language><publisher>Kancerološko združenje Slovenskega zdravniškega društva</publisher><publisher>Onkološki inštitut</publisher><publisher>Zveza slovenskih društev za boj proti raku</publisher><source>Onkološki vikend</source><rights>BY-NC-ND</rights><subject language_type_id="eng">Antagonists And Inhibitors</subject><subject language_type_id="eng">Antibodies, Monoclonal</subject><subject language_type_id="slv">Beljakovina-tirozinska kinaza</subject><subject language_type_id="eng">Drug Therapy</subject><subject language_type_id="eng">Neoplasms</subject><subject language_type_id="slv">Novotvorbe</subject><subject language_type_id="eng">Protein-Tyrosine Kinase</subject><subject language_type_id="slv">Protitelesa monoklonska</subject><subject language_type_id="eng">tumor</subject><title>Nova zdravila za zdravljenje malignih bolezni</title></Record>